134 related articles for article (PubMed ID: 16255681)
1. MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury.
Kandzari DE; Dery JP; Armstrong PW; Douglas DA; Zettler ME; Hidinger GK; Friesen AD; Harrington RA
Expert Opin Investig Drugs; 2005 Nov; 14(11):1435-42. PubMed ID: 16255681
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
; Alexander JH; Emery RW; Carrier M; Ellis SJ; Mehta RH; Hasselblad V; Menasche P; Khalil A; Cote R; Bennett-Guerrero E; Mack MJ; Schuler G; Harrington RA; Tardif JC
JAMA; 2008 Apr; 299(15):1777-87. PubMed ID: 18381567
[TBL] [Abstract][Full Text] [Related]
3. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
Tardif JC; Carrier M; Kandzari DE; Emery R; Cote R; Heinonen T; Zettler M; Hasselblad V; Guertin MC; Harrington RA;
J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1604-11. PubMed ID: 17532963
[TBL] [Abstract][Full Text] [Related]
4. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).
Kandzari DE; Labinaz M; Cantor WJ; Madan M; Gallup DS; Hasselblad V; Joseph D; Allen A; Green C; Hidinger KG; Krucoff MW; Christenson RH; Harrington RA; Tcheng JE
Am J Cardiol; 2003 Sep; 92(6):660-4. PubMed ID: 12972102
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.
Mehta RH; Alexander JH; Emery R; Ellis SJ; Hasselblad V; Khalil A; Carrier M; Harrington RA; Tardif JC;
Am Heart J; 2008 Apr; 155(4):600-8. PubMed ID: 18371465
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent.
Quintana M; Kahan T; Hjemdahl P
Am J Cardiovasc Drugs; 2004; 4(3):159-67. PubMed ID: 15134468
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial.
Carrier M; Emery R; Kandzari DE; Harrington R; Guertin MC; Tardif JC
J Cardiovasc Surg (Torino); 2008 Apr; 49(2):249-53. PubMed ID: 18431346
[TBL] [Abstract][Full Text] [Related]
8. Signalling pathways in ischaemic postconditioning.
Hausenloy DJ
Thromb Haemost; 2009 Apr; 101(4):626-34. PubMed ID: 19350104
[TBL] [Abstract][Full Text] [Related]
9. The reduction of infarct size--forty years of research.
Ferreira R
Rev Port Cardiol; 2010 Jun; 29(6):1037-53. PubMed ID: 20964114
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction.
Chakrabarti AK; Feeney K; Abueg C; Brown DA; Czyz E; Tendera M; Janosi A; Giugliano RP; Kloner RA; Weaver WD; Bode C; Godlewski J; Merkely B; Gibson CM
Am Heart J; 2013 Apr; 165(4):509-514.e7. PubMed ID: 23537966
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the 'MITOCARE' Study: a phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRO40303 for the reduction of reperfusion injury in patients undergoing percutaneous coronary intervention for acute myocardial infarction.
MITOCARE Study Group
Cardiology; 2012; 123(4):201-7. PubMed ID: 23202613
[TBL] [Abstract][Full Text] [Related]
12. Adenosine for myocardial protection in acute myocardial infarction.
Granger CB
Am J Cardiol; 1997 Jun; 79(12A):44-8. PubMed ID: 9223363
[TBL] [Abstract][Full Text] [Related]
13. The effect of remote ischaemic preconditioning on myocardial injury in patients undergoing off-pump coronary artery bypass graft surgery.
Hong DM; Mint JJ; Kim JH; Sohn IS; Lim TW; Lim YJ; Bahk JH; Jeon Y
Anaesth Intensive Care; 2010 Sep; 38(5):924-9. PubMed ID: 20865880
[TBL] [Abstract][Full Text] [Related]
14. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors.
Kerendi F; Kin H; Halkos ME; Jiang R; Zatta AJ; Zhao ZQ; Guyton RA; Vinten-Johansen J
Basic Res Cardiol; 2005 Sep; 100(5):404-12. PubMed ID: 15965583
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel treatment and the MEND-CABG II trial.
Oh J; Hong N; Kang SM
JAMA; 2008 Sep; 300(9):1021; author reply 1021-2. PubMed ID: 18768409
[No Abstract] [Full Text] [Related]
16. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
[TBL] [Abstract][Full Text] [Related]
17. Preconditioning and postconditioning: underlying mechanisms and clinical application.
Hausenloy DJ; Yellon DM
Atherosclerosis; 2009 Jun; 204(2):334-41. PubMed ID: 19081095
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotection: chances and challenges of its translation to the clinic.
Heusch G
Lancet; 2013 Jan; 381(9861):166-75. PubMed ID: 23095318
[TBL] [Abstract][Full Text] [Related]
19. Does Remote Ischaemic Preconditioning Protect Kidney and Cardiomyocytes After Coronary Revascularization? A Double Blind Controlled Clinical Trial.
Nouraei SM; Baradari AG; Jazayeri A
Med Arch; 2016 Oct; 70(5):373-378. PubMed ID: 27994300
[TBL] [Abstract][Full Text] [Related]
20. 3',4'-Dihydroxyflavonol reduces infarct size and injury associated with myocardial ischaemia and reperfusion in sheep.
Wang S; Dusting GJ; May CN; Woodman OL
Br J Pharmacol; 2004 Jun; 142(3):443-52. PubMed ID: 15148246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
